Xianwei Meibomian Gland Thermal Pulsation Device

Xianwei Medical’s Meibomian Gland Thermal Pulsation Device delivers controlled heat and pressure therapy to restore meibomian gland function in dry eye patients. Targeting the approximately 87.6% of dry eye cases in mainland China attributed to meibomian gland dysfunction (MGD), the device offers a domestic alternative to imported thermal pulsation systems at reduced cost points.

Product Overview

Dry eye disease affects over 360 million people in China, making it the second most common ocular condition after myopia. Among affected patients, evaporative dry eye caused by MGD represents the dominant subtype. The meibomian glands produce lipids essential for tear film stability; when obstructed, tear evaporation accelerates, causing ocular surface damage and discomfort.

Traditional MGD treatment relies on warm compresses and manual gland expression—approaches with inconsistent results and poor patient tolerance. Thermal pulsation therapy addresses these limitations through device-controlled heating and vectored pressure, achieving more complete gland evacuation than manual techniques.

The Xianwei device applies thermal energy to the eyelid’s inner surface while simultaneously delivering calibrated external pressure, liquefying inspissated meibum and expressing it from obstructed glands. Treatment effects from single sessions have been documented to persist for one year or longer in clinical studies of similar devices.

Key Features

Designed for evaporative dry eye caused by meibomian gland dysfunction—87.6% of dry eye cases in China—the Xianwei device combines controlled heat and synchronized pressure for single-session gland clearance.

• Controlled Thermal Delivery: Precisely regulated heating to therapeutic temperatures, optimizing meibum liquefaction while maintaining tissue safety margins.

• Vectored Pressure Application: Mechanical expression synchronized with thermal treatment, ensuring effective gland evacuation.

• Domestic Manufacturing: Production through CDMO partnerships in China, enabling cost structures below imported alternatives.

• Single-Session Efficacy: Treatment protocol designed for meaningful symptom relief from individual treatment sessions, reducing patient visit burden.

Clinical Applications

Primary Indication: Meibomian gland dysfunction causing evaporative dry eye disease

Target Patient Population:

• Patients with symptomatic dry eye and confirmed MGD
• Cases refractory to conservative warm compress therapy
• Patients seeking longer-duration treatment effects versus daily management

Treatment Setting: Designed for outpatient ophthalmology clinic deployment, with sessions completed during standard office visits.

Market Context

The dry eye treatment market in China continues expanding, driven by increased digital device usage and aging demographics. Imported thermal pulsation systems (such as LipiFlow) carry significant acquisition costs that limit deployment primarily to premium clinical settings.

Xianwei Medical’s domestic production strategy targets broader market accessibility through reduced equipment and consumable pricing. The company has established framework agreements for Southeast Asian distribution, indicating international market ambitions beyond China.

Regulatory Status

As a Class II medical device under NMPA classification, the thermal pulsation device follows a shorter regulatory pathway than Class III surgical robots. The company projected NMPA clearance by late 2024, with commercial sales anticipated in 2025.

Frequently Asked Questions

How does thermal pulsation treatment work?

The device applies controlled heat to the inner eyelid surface, raising meibomian gland secretions to temperatures where the lipids liquefy. Simultaneously, calibrated pressure is applied to the outer eyelid, expressing the softened meibum from obstructed glands. This combined approach achieves more complete gland clearing than heat or pressure alone.

How long do treatment effects last?

Clinical data from similar thermal pulsation devices indicates that single treatment sessions can provide symptom relief lasting one year or longer in responding patients. Individual results vary based on disease severity and gland status.

How does this compare to LipiFlow?

The Xianwei device targets functional equivalence to imported thermal pulsation systems while leveraging domestic manufacturing to reduce costs. Specific comparative performance data will depend on clinical validation studies. The company positions its device as enabling thermal pulsation therapy access for a broader range of clinical settings than premium-priced imports permit.